214 related articles for article (PubMed ID: 26441077)
1. Malignancy associated hypercalcaemia-responsiveness to IV bisphosphonates and prognosis in a palliative population.
Mallik S; Mallik G; Macabulos ST; Dorigo A
Support Care Cancer; 2016 Apr; 24(4):1771-7. PubMed ID: 26441077
[TBL] [Abstract][Full Text] [Related]
2. The management of hypercalcaemia in advanced cancer.
Pettifer A; Grant S
Int J Palliat Nurs; 2013 Jul; 19(7):327-31. PubMed ID: 24273809
[TBL] [Abstract][Full Text] [Related]
3. Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemia.
Sims EC; Rogers PB; Besser GM; Plowman PN
Clin Oncol (R Coll Radiol); 1998; 10(6):407-9. PubMed ID: 9890546
[TBL] [Abstract][Full Text] [Related]
4. Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy.
Wimalawansa SJ
Clin Endocrinol (Oxf); 1994 Nov; 41(5):591-5. PubMed ID: 7828347
[TBL] [Abstract][Full Text] [Related]
5. Denosumab in hypercalcemia of malignancy: a case series.
Dietzek A; Connelly K; Cotugno M; Bartel S; McDonnell AM
J Oncol Pharm Pract; 2015 Apr; 21(2):143-7. PubMed ID: 24415364
[TBL] [Abstract][Full Text] [Related]
6. [The significance of early diagnosis of cancer-related hypercalcaemia].
Radványi I; Csikós A; Balogh S
Orv Hetil; 2013 Sep; 154(35):1367-73. PubMed ID: 23974972
[TBL] [Abstract][Full Text] [Related]
7. Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy.
Adhikaree J; Newby Y; Sundar S
BMJ Case Rep; 2014 Jan; 2014():. PubMed ID: 24481018
[TBL] [Abstract][Full Text] [Related]
8. Survival in breast cancer patients after the first episode of hypercalcaemia.
Kristensen B; Ejlertsen B; Mouridsen HT; Loft H
J Intern Med; 1998 Sep; 244(3):189-98. PubMed ID: 9747741
[TBL] [Abstract][Full Text] [Related]
9. Pathogenesis and management of cancer associated hypercalcaemia.
Ralston SH
Cancer Surv; 1994; 21():179-96. PubMed ID: 8564993
[TBL] [Abstract][Full Text] [Related]
10. Tumour induced hypercalcaemia: a case for active treatment.
O'Rourke NP; McCloskey EV; Kanis JA
Clin Oncol (R Coll Radiol); 1994; 6(3):172-6. PubMed ID: 8086352
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of malignancy associated hypercalcemia].
Tai N; Inoue D
Clin Calcium; 2014 Aug; 24(8):1223-8. PubMed ID: 25065875
[TBL] [Abstract][Full Text] [Related]
12. Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy.
Morton AR; Cantrill JA; Craig AE; Howell A; Davies M; Anderson DC
Br Med J (Clin Res Ed); 1988 Mar; 296(6625):811-4. PubMed ID: 3130925
[TBL] [Abstract][Full Text] [Related]
13. Analysis on survival and prognostic factors for cancer patients with malignancy-associated hypercalcemia.
Zhang SJ; Hu Y; Cao J; Qian HL; Jiao SC; Liu ZF; Tao HT; Han L
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6715-9. PubMed ID: 24377594
[TBL] [Abstract][Full Text] [Related]
14. Hypercalcemic complication in patients with oral squamous cell carcinoma.
Iwase M; Takemi T; Manabe M; Nagumo M
Int J Oral Maxillofac Surg; 2003 Apr; 32(2):174-80. PubMed ID: 12729778
[TBL] [Abstract][Full Text] [Related]
15. [Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia.].
Tai N; Inoue D
Clin Calcium; 2018; 28(11):1503-1508. PubMed ID: 30374007
[TBL] [Abstract][Full Text] [Related]
16. Systematic review of bisphosphonates for hypercalcaemia of malignancy.
Saunders Y; Ross JR; Broadley KE; Edmonds PM; Patel S;
Palliat Med; 2004 Jul; 18(5):418-31. PubMed ID: 15332420
[TBL] [Abstract][Full Text] [Related]
17. Symptomatic hypercalcaemia in lung cancer.
Campbell JH; Ralston S; Boyle IT; Banham SW
Respir Med; 1991 May; 85(3):223-7. PubMed ID: 1831917
[TBL] [Abstract][Full Text] [Related]
18. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
Guay DR
Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
[TBL] [Abstract][Full Text] [Related]
19. Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis.
Penel N; Dewas S; Doutrelant P; Clisant S; Yazdanpanah Y; Adenis A
Support Care Cancer; 2008 Apr; 16(4):387-92. PubMed ID: 17710443
[TBL] [Abstract][Full Text] [Related]
20. Treatment of hypercalcaemia of malignancy in adults.
Mc Donald D; Drake MT; Crowley RK
Clin Med (Lond); 2023 Sep; 23(5):503-507. PubMed ID: 37775175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
